Jean-Marc Guettier1, Jean Y Park1, Elaine K Cochran1, Christine Poitou2, Arnaud Basdevant2,3, Muriel Meier4,5, Karine Clément2,3, Jocelyne Magré4,5, Phillip Gorden1. 1. Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 2. INSERM, U872 Equipe 7 Paris; Université Pierre et Marie Curie-Paris6, Centre de Recherche des Cordeliers, UMRS872, Paris. 3. AP/HP, Department d'Endocrinologie, hôpital Pitié Salpétrière, Paris. 4. INSERM, U680, Paris. 5. Université Pierre et Marie Curie-Paris6, Faculté de Médecine, UMRS680, Paris, France.
Abstract
AIMS/HYPOTHESIS: Partial lipodystrophy (PL) is most commonly characterized by loss of subcutaneous fat in the extremities with preservation of truncal fat and is associated with insulin resistance, diabetes and hyperlipidaemia. Recombinant human leptin (r-metHuLeptin) therapy has been shown to be effective in treating metabolic abnormalities associated with congenital or acquired generalized lipodystrophy and PL associated with lamin A/C (LMNA) gene mutations or highly active antiretroviral therapy (HAART). Our aim was to assess the effectiveness of leptin therapy in treating metabolic complications of PL associated with heterozygous peroxisome proliferator activated receptor gamma (PPARG) mutations. This is the first report to detail the clinical response of a patient with PL due to a PPARG mutation treated with r-metHuLeptin. METHODS: A 36-year-old female with PL associated with a heterozygous PPARG mutation complicated by poorly controlled diabetes and severe, refractory hypertriglyceridaemia was enrolled in a National Institutes of Health (NIH) protocol to evaluate the role of r-metHuLeptin in lipodystrophy. The patient received escalating doses of r-metHuLeptin until a dose 0.12 mg/kg/day was reached. Metabolic parameters, including serum chemistries, fasting blood glucose, glycated haemoglobin (HbA1c), lipid profile, an oral glucose tolerance test (OGTT), an insulin tolerance test (ITT), liver volume, percentage body fat and energy expenditure were followed at regular time intervals over 18 months of therapy. RESULTS: Eighteen months of r-MetHuLeptin therapy was associated with a marked improvement in glucose homeostasis as evidenced by normalization of the fasting blood glucose (baseline = 8.3 mmol/l; 18 months = 4.9 mmol/l), lowering of HbA1c (baseline = 9.9%; 18 months = 7.2%) and improved tolerance to an oral glucose load. In addition, a striking amelioration in the patient's refractory, severe hypertriglyceridaemia was observed (baseline = 21.15 mmol/l; 18 months = 5.96 mmol/l). CONCLUSION: r-MetHuLeptin is effective in treating metabolic complications associated with PL due to PPARG mutations. In the context of previously published work, our findings suggest that the response to r-MetHuLeptin is independent of the aetiology in lipodystrophy.
AIMS/HYPOTHESIS: Partial lipodystrophy (PL) is most commonly characterized by loss of subcutaneous fat in the extremities with preservation of truncal fat and is associated with insulin resistance, diabetes and hyperlipidaemia. Recombinant humanleptin (r-metHuLeptin) therapy has been shown to be effective in treating metabolic abnormalities associated with congenital or acquired generalized lipodystrophy and PL associated with lamin A/C (LMNA) gene mutations or highly active antiretroviral therapy (HAART). Our aim was to assess the effectiveness of leptin therapy in treating metabolic complications of PL associated with heterozygous peroxisome proliferator activated receptor gamma (PPARG) mutations. This is the first report to detail the clinical response of a patient with PL due to a PPARG mutation treated with r-metHuLeptin. METHODS: A 36-year-old female with PL associated with a heterozygous PPARG mutation complicated by poorly controlled diabetes and severe, refractory hypertriglyceridaemia was enrolled in a National Institutes of Health (NIH) protocol to evaluate the role of r-metHuLeptin in lipodystrophy. The patient received escalating doses of r-metHuLeptin until a dose 0.12 mg/kg/day was reached. Metabolic parameters, including serum chemistries, fasting blood glucose, glycated haemoglobin (HbA1c), lipid profile, an oral glucose tolerance test (OGTT), an insulin tolerance test (ITT), liver volume, percentage body fat and energy expenditure were followed at regular time intervals over 18 months of therapy. RESULTS: Eighteen months of r-MetHuLeptin therapy was associated with a marked improvement in glucose homeostasis as evidenced by normalization of the fasting blood glucose (baseline = 8.3 mmol/l; 18 months = 4.9 mmol/l), lowering of HbA1c (baseline = 9.9%; 18 months = 7.2%) and improved tolerance to an oral glucose load. In addition, a striking amelioration in the patient's refractory, severe hypertriglyceridaemia was observed (baseline = 21.15 mmol/l; 18 months = 5.96 mmol/l). CONCLUSION: r-MetHuLeptin is effective in treating metabolic complications associated with PL due to PPARG mutations. In the context of previously published work, our findings suggest that the response to r-MetHuLeptin is independent of the aetiology in lipodystrophy.
Authors: S Shackleton; D J Lloyd; S N Jackson; R Evans; M F Niermeijer; B M Singh; H Schmidt; G Brabant; S Kumar; P N Durrington; S Gregory; S O'Rahilly; R C Trembath Journal: Nat Genet Date: 2000-02 Impact factor: 38.330
Authors: J Magré; M Delépine; E Khallouf; T Gedde-Dahl; L Van Maldergem; E Sobel; J Papp; M Meier; A Mégarbané; A Bachy; A Verloes; F H d'Abronzo; E Seemanova; R Assan; N Baudic; C Bourut; P Czernichow; F Huet; F Grigorescu; M de Kerdanet; D Lacombe; P Labrune; M Lanza; H Loret; F Matsuda; J Navarro; A Nivelon-Chevalier; M Polak; J J Robert; P Tric; N Tubiana-Rufi; C Vigouroux; J Weissenbach; S Savasta; J A Maassen; O Trygstad; P Bogalho; P Freitas; J L Medina; F Bonnicci; B I Joffe; G Loyson; V R Panz; F J Raal; S O'Rahilly; T Stephenson; C R Kahn; M Lathrop; J Capeau Journal: Nat Genet Date: 2001-08 Impact factor: 38.330
Authors: C Vigouroux; J Magré; M C Vantyghem; C Bourut; O Lascols; S Shackleton; D J Lloyd; B Guerci; G Padova; P Valensi; A Grimaldi; R Piquemal; P Touraine; R C Trembath; J Capeau Journal: Diabetes Date: 2000-11 Impact factor: 9.461
Authors: Elif Arioglu Oral; Vinaya Simha; Elaine Ruiz; Alexa Andewelt; Ahalya Premkumar; Peter Snell; Anthony J Wagner; Alex M DePaoli; Marc L Reitman; Simeon I Taylor; Phillip Gorden; Abhimanyu Garg Journal: N Engl J Med Date: 2002-02-21 Impact factor: 91.245
Authors: Jocelyne Magré; Marc Delépine; Lionel Van Maldergem; Jean-Jacques Robert; J Antonie Maassen; Muriel Meier; Vanessa R Panz; Chong Ae Kim; Nadia Tubiana-Rufi; Paul Czernichow; Eva Seemanova; Charles R Buchanan; Didier Lacombe; Corinne Vigouroux; Olivier Lascols; C Ronald Kahn; Jacqueline Capeau; Mark Lathrop Journal: Diabetes Date: 2003-06 Impact factor: 9.461
Authors: David B Savage; Garry D Tan; Carlo L Acerini; Susan A Jebb; Maura Agostini; Mark Gurnell; Rachel L Williams; A Margot Umpleby; E Louise Thomas; Jimmy D Bell; Adrian K Dixon; Fidelma Dunne; Romina Boiani; Saverio Cinti; Antonio Vidal-Puig; Fredrik Karpe; V Krishna K Chatterjee; Stephen O'Rahilly Journal: Diabetes Date: 2003-04 Impact factor: 9.461
Authors: Maura Agostini; Erik Schoenmakers; Junaid Beig; Louise Fairall; Istvan Szatmari; Odelia Rajanayagam; Frederick W Muskett; Claire Adams; A David Marais; Stephen O'Rahilly; Robert K Semple; Laszlo Nagy; Amit R Majithia; John W R Schwabe; Dirk J Blom; Rinki Murphy; Krishna Chatterjee; David B Savage Journal: Diabetes Date: 2018-04-05 Impact factor: 9.461